Cardiopulmonary Bypass clinical trials at University of California Health

1 research study open to eligible people

Showing trials for

  • ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE

    open to eligible people ages 18-90

    The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the clinical consequences of AKI (MAKE) at 90 days in adult participants with CKD who undergo non-emergent cardiac surgery with CPB.

    at UCSF

Last updated: